Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in XENE — Xenon Pharmaceuticals Inc.

CIK 1423053 MIAMI, FL
Back to XENE Full portfolio

Position in XENE

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$154,271,368
+$95,054,602 QoQ
Shares Held
2,652,990
+100.8% QoQ
Ownership
2.74%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in XENE Over Time

Shares Held

Position Value (USD)

Derivatives in XENE

reported options exposure · as of Mar 31, 2026
CallValue
$5,954,560
CallShares
102,400
PutValue
$7,617,650
PutShares
131,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. XENE ranks #10 (2.7% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in XENE

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $5,954,560 102,400
2026-03-31 $7,617,650 131,000
2026-03-31 $154,271,368 2,652,990
2025-12-31 $2,760,912 61,600
2025-12-31 $2,102,058 46,900
2025-12-31 $59,216,766 1,321,213
2025-09-30 $1,176,395 29,300
2025-09-30 $38,507,784 959,098
2025-09-30 $895,345 22,300
2025-06-30 $1,145,580 36,600
2025-06-30 $669,820 21,400
2025-06-30 $3,757,408 120,045
2025-03-31 $258,335 7,700
2025-03-31 $218,075 6,500
2025-03-31 $23,051,802 687,088
2024-12-31 $12,830,277 327,303
2024-12-31 $576,240 14,700
2024-12-31 $82,320 2,100
2024-09-30 $141,732 3,600
2024-09-30 $661,416 16,800
2024-09-30 $28,444,981 722,504
2024-06-30 $1,239,882 31,800
2024-06-30 $280,728 7,200
2024-06-30 $29,972,626 768,726
2024-03-31 $486,465 11,300
2024-03-31 $452,025 10,500
2024-03-31 $55,408,578 1,287,075
2023-12-31 $58,350,833 1,266,844
2023-12-31 $778,414 16,900
2023-12-31 $7,005,726 152,100
2023-09-30 $703,696 20,600
2023-09-30 $24,715,579 723,524
2023-09-30 $713,944 20,900
2023-06-30 $161,700 4,200
2023-06-30 $19,288,961 501,012
2023-06-30 $527,450 13,700
2023-03-31 $1,381,494 38,600
2023-03-31 $31,181,464 871,234
2023-03-31 $268,425 7,500
2022-12-31 $45,912,567 1,164,407
2022-12-31 $737,341 18,700
2022-12-31 $1,182,900 30,000
2022-09-30 $375,440 10,400
2022-09-30 $41,226,272 1,142,002
2022-09-30 $906,110 25,100
2022-06-30 $358,956 11,800
2022-06-30 $422,838 13,900
2022-06-30 $50,133,345 1,648,039
2022-03-31 $44,053,814 1,441,080
2022-03-31 $553,317 18,100

Report a Problem

Category
Description
Email (optional, for follow-up)